secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001517022-24-000059
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Therapeutics appoints Erik Ostrowski as CFO and Chief Business Officer
-----------------------------------------------------------------------------

- Erik Ostrowski appointed Senior VP, CFO, Chief Business Officer and Treasurer, effective June 24, 2024.
- Base salary of $540,000, annual bonus target up to 45% of base salary.
- Granted options to purchase 500,000 shares (4-year vest) and 350,000 RSUs (3-year vest).
- Ostrowski previously served as President/Interim CEO and CFO of AVROBIO, Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000059/0001517022-24-000059-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702224000059/akba-20240621.htm
  HTML page:      https://secwatch.observer/filing/0001517022-24-000059

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer